New mAbs on the Block: A (Rocking) Research Update on Biosimilar Uptake and Benefit Design Strategies

Published: March 16, 2022

2022 pbconference feature

– Describe the therapeutic areas, pipeline, and regulatory environment affecting the biosimilar landscape
– Report results of current research on barriers to biosimilar adoption and impact of benefit design and formulary policies on utilization
– Discuss prospective payer management strategies in anticipation of market entry of pharmacy benefit biosimilars


Cate Lockhart, MS, PharmD, Ph.D., Executive Director, Biologics and Biosimilars Collective Intelligence Consortium

Jennifer Snow, MPH, Vice President of Reimbursement Policy Insights, AmerisourceBergen/ Xcenda

View All Resources